Shah Capital ends campaign against Novavax board after Sanofi deal
(Reuters) - Hedge fund Shah Capital said on Monday it would withdraw its campaign against the re-election of three directors on Novavax's board, after the COVID-19 vaccine maker struck a licensing deal with Sanofi. Under a deal signed on May 10, the …